Covered recipient · General Payments record
BRYAN P CRUZ
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,255.52
- Reported across 128 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $643.36 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $308.27 | 18 |
| Bayer HealthCare Pharmaceuticals Inc. | $79.55 | 3 |
| PFIZER INC. | $59.25 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $46.05 | 2 |
| Novo Nordisk AS | $35.01 | 2 |
| Amgen Inc. | $33.83 | 2 |
| CSL Behring | $26.38 | 1 |
| Exact Sciences Corporation | $20.84 | 1 |
| Phadia US Inc. | $18.23 | 1 |
| GlaxoSmithKline, LLC. | $15.95 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $9.94 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519264 | CMS |
| ABBVIE INC. | $12.27 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519266 | CMS |
| ABBVIE INC. | $20.16 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519268 | CMS |
| ABBVIE INC. | $31.16 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519270 | CMS |
| ABBVIE INC. | $12.54 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519272 | CMS |
| ABBVIE INC. | $13.63 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519274 | CMS |
| ABBVIE INC. | $12.69 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519276 | CMS |
| ABBVIE INC. | $13.91 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519278 | CMS |
| ABBVIE INC. | $15.14 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519280 | CMS |
| ABBVIE INC. | $24.80 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519282 | CMS |
| ABBVIE INC. | $17.79 | 07/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519284 | CMS |
| ABBVIE INC. | $22.60 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519286 | CMS |
| ABBVIE INC. | $2.69 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519288 | CMS |
| ABBVIE INC. | $18.49 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519290 | CMS |
| ABBVIE INC. | $22.55 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519292 | CMS |
| ABBVIE INC. | $19.02 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519294 | CMS |
| ABBVIE INC. | $24.95 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519296 | CMS |
| ABBVIE INC. | $13.94 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103519298 | CMS |
| Amgen Inc. | $20.17 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117231469 | CMS |
| Amgen Inc. | $13.66 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117231471 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $31.68 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086234143 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $23.10 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086257006 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $24.77 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086185646 | CMS |
| Boston Scientific Corporation | $20.09 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1069135538 | CMS |
| Boston Scientific Corporation | $25.96 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1069135540 | CMS |
| CSL Behring | $26.38 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134616857 | CMS |
| Exact Sciences Corporation | $20.84 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114624617 | CMS |
| GlaxoSmithKline, LLC. | $15.95 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115769748 | CMS |
| Novo Nordisk Inc | $21.68 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097532243 | CMS |
| Novo Nordisk Inc | $13.33 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097162330 | CMS |
| PFIZER INC. | $21.87 | 01/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131179913 | CMS |
| PFIZER INC. | $19.48 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131065894 | CMS |
| PFIZER INC. | $17.90 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131377127 | CMS |
| Phadia US Inc. | $18.23 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067576574 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.